



“LO MEJOR DEL AÑO” EN VIH y VHC

*Dr. Antonio Antela. Unidad de Enfermedades Infecciosas, Hospital
Clínico Universitario de Santiago, Santiago de Compostela*

1. Anne Boerekamps, Guido E. van den Berk, Fanny N. Lauw, Eliane M. Leyten, Marjo E. van Kasteren, Arne van Eeden, Dirk Posthouwer, Mark A. Claassen, Anton S. Dofferhoff, Dominique W. M. Verhagen, Wouter F. Bierman, Kamilla D. Lettinga, Frank P. Kroon, Corine E. Delsing, Paul H. Groeneveld, Robert Soetekouw, Edgar J. Peters, Sebastiaan J. Hullegie, Stephanie Popping, David A. M. C. van de Vijver, Charles A. Boucher, Joop E. Arend, and Bart J. Rijnders. **Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy.** HCV Incidence Decline in HIV-Positive MSM, CID 2018:66 (1 May).
2. Krishna P. Reddy, MD; Chung Yin Kong, PhD; Emily P. Hyle, MD, SM; Travis P. Baggett, MD, MPH; Mingshu Huang, PhD; Robert A. Parker, ScD; A. David Paltiel, PhD; Elena Losina, PhD, MSc; Milton C. Weinstein, PhD; Kenneth A. Freedberg, MD, MSc; Rochelle P. Walensky, MD, MPH. **Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States.** JAMA Internal Medicine Published online September 18, 2017.
3. J. Hakim, V. Musiime, A.J. Szubert, J. Mallewa, A. Siika, C. Agutu, S. Walker, S.L. Pett, M. Bwakura-Dangarembizi, A. Lugemwa, S. Kaunda, M. Karoney, G. Musoro, S. Kabahenda, K. Nathoo, K. Maitland, A. Griffiths, M.J. Thomason, C. Kityo, P. Mugenyi, A.J. Prendergast, A.S. Walker, and D.M. Gibb, for the REALITY Trial Team. **Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.** N Engl J Med 377;3 nejm.org July 20, 2017, The new england journal of medicine.
4. The Antiretroviral Therapy Cohort Collaboration. **Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.** The Lancet HIV 2017. www.thelancet.com/hiv Published online May 10, 2017.
5. David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Daniel Podzamczar, Thomas Lutz, Jonathan B Angel, Gary J Richmond, Bonaventura Clotet, Felix Gutierrez, Louis Sloan*, Marty St Clair, Miranda Murray, Susan L Ford, Joseph Mrus, Parul Patel, Herta Crauwels, Sandy K Griffith, Kenneth C Sutton, David Dorey, Kimberly Y Smith, Peter E Williams, William R Spreen. **Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.** www.thelancet.com Published online July 24, 2017.



6. Federico Pulido, Esteban Ribera, María Lagarde, Ignacio Pérez-Valero, Rosario Palacios, José A. Iribarren, Antoni Payeras, Pere Domingo, José Sanz, Miguel Cervero, Adrián Curran, Francisco J. Rodríguez-Gómez, María J. Téllez, Pablo Ryan, Pilar Barrufet, Hernando Knobel, Antonio Rivero, Belén Alejos, María Yllescas and José R. Arribas for the DUAL-GESIDA-8014-RIS-EST45 Study Group. **Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.** *Darunavir/Ritonavir + 3TC Dual Therapy* • CID 2017:65 (15 December).
7. Joel Gallant, Adriano Lazzarin, Anthony Mills, Chloe Orkin, Daniel Podzamczar, Pablo Tebas, Pierre-Marie Girard, Indira Brar, Eric S Daar, David Wohl, Jürgen Rockstroh, Xuelian Wei, Joseph Custodio, Kirsten White, Hal Martin, Andrew Cheng, Erin Quirk. **Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.** www.thelancet.com Published online August 31, 2017.
8. Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, José R Arribas, Joseph Gathe, Joseph J Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer, on behalf of the EMERALD study group. **Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.** www.thelancet.com/hiv Published online October 6, 2017.
9. Raúl U Hernández-Ramírez, Meredith S Shiels, Robert Dubrow, Eric A Engels. **Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study.** *The Lancet HIV* 2017 www.thelancet.com/hiv Published online August 10, 2017.
10. Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, José R Arribas, Joseph Gathe, Joseph J Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer, on behalf of the EMERALD study group. **Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.** www.thelancet.com/hiv Published online October 6, 2017.



11. Paul E Sax, Anton Pozniak, M Luisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes, Will Garner, Joseph Custodio, Kirsten White, Devi SenGupta, Andrew Cheng, Erin Quirk. **Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.** www.thelancet.com Published online August 31, 2017.
12. Jean-Michel Molina, Birgit Grund, Fred Gordin, Ian Williams, Mauro Schechter, Marcello Losso, Matthew Law, Ernest Ekong, Noluthando Mwelase, Athanasios Skoutelis, Martin J Wiselka, Linos Vandekerckhove, Thomas Benfield, David Munroe, Jens D Lundgren, James D Neaton, for the INSIGHT START study group. **Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.** LANCET HIV 2018 www.thelancet.com/hiv Vol 5 April 2018.
13. Pedro Cahn, Richard Kaplan, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Anchalee Avihingsanon, Winai Ratanasuwan, Evelyn Rojas, Mohammed Rassool, Mark Bloch, Linos Vandekerckhove, Peter Ruane, Yazdan Yazdanpanah, Christine Katlama, Xia Xu, Anthony Rodgers, Lilly East, Larissa Wenning, Sandy Rawlins, Brenda Homony, Peter Sklar, Bach-Yen Nguyen, Randi Leavitt, Hedy Teppler, for the ONCEMRK Study Group. **Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.** The Lancet HIV 2017 www.thelancet.com/hiv Published online September 11, 2017.